氘可来昔替尼(Deucravacitinib) - 药物靶点：TYK2_在研适应症：红皮病性银屑病，寻常性银屑病，脓疱型银屑病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Deucravacitinib (USAN)、BMS-986165、BMS-986165-01

+ [4]

靶点

TYK2

作用方式

抑制剂

作用机制

TYK2抑制剂(酪氨酸蛋白激酶TYK2抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病感染+ [5]

在研适应症

红皮病性银屑病寻常性银屑病脓疱型银屑病+ [12]

非在研适应症

斑秃泛发性脓疱型银屑病环形肉芽肿+ [8]

原研机构

Bristol Myers Squibb Co.

在研机构

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIGBristol-Myers Squibb Australia Pty Ltd.

+ [2]

非在研机构

Dartmouth-Hitchcock Medical Center

百时美施贵宝（中国）投资有限公司

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2022-09-09),

斑块状银屑病

最高研发阶段(中国)批准上市

特殊审评特殊审批 (中国)

登录后查看时间轴

结构/序列

分子式C20H22N8O3

InChIKeyBZZKEPGENYLQSC-FIBGUPNXSA-N

CAS号1609392-27-9

关联

89

项与氘可来昔替尼相关的临床试验

NCT06979453

/ Not yet recruiting临床3期

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

开始日期2025-08-26

申办/合作机构

Bristol Myers Squibb Co.

NCT07012057

/ Not yet recruiting临床2期IIT

A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis

Background:
Dermatomyositis (DM) and juvenile dermatomyositis (JDM) are diseases that weaken the immune system. DM and JDM can affect the muscles, skin, joints, and lungs and cause skin rashes and muscle inflammation. Symptoms include weakness, pain, fatigue, and rash. Not everyone responds to current treatments. The FDA has approved a drug called deucravacitinib to treat people with plaque psoriasis. Researchers want to find out if this drug can help people with DM or JDM, too.
Objective:
To test deucravacitinib in people with DM or JDM.
Eligibility:
People aged 18 years and older with DM or JDM.
Design:
Participants will have 9 clinic visits over 28 weeks.
Participants will be screened. They will have a physical exam with blood and urine tests. They will have a test of their heart function. They will complete a short questionnaire about their daily life, pain level, and ability to walk, eat, and do other activities.
Deucravacitinib is a pill taken by mouth twice per day at home. Participants will come to the clinic once every 4 weeks for 24 weeks while they are taking the drug. They will have a final visit 4 weeks after their last dose of the study drug. Blood and urine tests will be repeated during these visits. Each visit may take up to 6 hours.
If the drug is helping them, participants may extend their treatment beyond the first 24 weeks. Then they will visit the clinic every 3 months....

开始日期2025-07-22

申办/合作机构-

NCT07013838

/ Not yet recruiting临床4期IIT

Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu's Arteritis: The TYK-TAK Trial

This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.

开始日期2025-06-15

申办/合作机构

Chinese SLE Treatment And Research Group

100 项与氘可来昔替尼相关的临床结果

登录后查看更多信息

100 项与氘可来昔替尼相关的转化医学

登录后查看更多信息

100 项与氘可来昔替尼相关的专利（医药）

登录后查看更多信息

308

项与氘可来昔替尼相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan

Article

作者: van de Wetering, Gijs ; Tada, Yayoi ; Roberts, David ; Hikichi, Yusuke ; Kim, Hyunchung ; Smith, Martina

OBJECTIVE:

This study aimed to evaluate the cost-effectiveness of deucravacitinib vs. apremilast as a treatment for moderate-to-severe psoriasis patients from a Japan healthcare system perspective.

METHODS:

A Markov sequence model was developed, consisting of an induction phase, maintenance phase, best supportive care and death. Clinical inputs were predominantly derived from the POETYK-PSO-1 and -2 trials (NCT03624127 and NCT03611751), and cost and resource use inputs were derived from several Japanese sources, including Ministry of Health and Welfare (MHLW) data and the outputs of a Delphi survey with Japanese clinical experts. Health-related quality of life inputs were based on the change in utility associated with different levels of Psoriasis Area and Severity Index (PASI) response. Deterministic and probabilistic sensitivity analyses were conducted to account for uncertainty around the base case and several scenario analyses were performed to explore structural uncertainty related to assumptions and methodological choices.

RESULTS:

In the base case, treatment with deucravacitinib results in a discounted QALY gain of 0.30 and discounted incremental costs of ¥459,771 compared to apremilast, resulting in an ICUR of ¥1,546,713 per QALY which is below the Japanese willingness to pay threshold of ¥5,000,000 per QALY. Deterministic and probabilistic sensitivity analyses support the results of the base case. The latter shows that deucravacitinib has a 97.8% probability of being cost-effective compared to apremilast at the ¥5,000,000 per QALY threshold. The outcomes of all scenarios confirmed the cost-effectiveness of deucravacitinib compared to apremilast, with deucravacitinib being dominant in one scenario.

CONCLUSIONS:

Deucravacitinib is cost-effective compared to apremilast in patients with moderate-to-severe plaque psoriasis in Japan, primarily driven by improvements in health-related quality of life associated with a more favorable PASI response. This conclusion is supported by extensive sensitivity and scenario analyses.

2025-12-31·ANNALS OF MEDICINE

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis

Review

作者: Wang, Bangmao ; Yang, Huibin ; Zhang, Qingyu ; Zhao, Yuxuan ; An, Ting ; Shi, Xiaojing

BACKGROUND AND OBJECTIVE:

Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.

PATIENTS AND METHODS:

Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions.

RESULTS:

A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (versus placebo) showed a trend towards increased risks of VTE (OR=1.36, 95% CI: 0.23-8.03) and CVE (OR=1.08, 95% CI: 0.24-4.85), and ranked higher than placebo for the risk of VTE [P-score=0.766 (versus 0.722)]. Notably, Deucravacitinib ranked lowest for all cardiovascular risks, and significantly decreased the risks of VTE (OR=0.03, 95% CI: 0.00-0.87) and CVE (OR=0.03, 95% CI: 0.00-0.87) compared with placebo.

CONCLUSIONS:

Although a trend of increased cardiovascular risks was found considering dose, no significantly increased cardiovascular risk was associated with JAKinibs in IBD patients, and Deucravacitinib significantly decreased the risks of VTE and CVE.

2025-09-01·BIOMEDICAL CHROMATOGRAPHY

A Validated Quantitative LC–MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study

Article

作者: Haque, M. Akiful ; Mahesh, Pottabattula

ABSTRACT:

We developed and validated a novel analytical methodology for the precise quantification of deucravacitinib, an oral TYK2 inhibitor for treating moderate‐to‐severe plaque psoriasis in adults. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) was employed in this method for sensitive detection of the compound in rat plasma. Analytical separation was performed utilizing an ACE C18 column (4.6 × 100 mm, 5‐μm particle size) with a carefully optimized mobile phase composition of methanol and 2‐mM ammonium formate (90:10, v/v), maintained at a consistent flow rate of 0.9 mL/min. Detection was executed in positive ionization mode, targeting multiple reaction monitoring (MRM) transitions of m/z 426.8 → 358.4 for the analyte and m/z 394.1 → 363.2 for the internal standard. The validation of the analytical method encompassed an assessment of selectivity, linearity, accuracy, precision, recovery, and stability. This method demonstrated stability, specificity, and no matrix effect at three concentration levels (1.606, 267.600, 507.780 ng/mL). The method's lower limit of quantification (LLOQ) is 0.556 ng/mL. The calibration curve demonstrates linearity from the LLOQ up to 668.132 ng/mL, exhibiting a high correlation coefficient (r2 = 0.9976). The intraday and interday precisions were less than 6.62% and 5.95%, respectively, with accuracies ranging from 90.68% to 103.80%. The recovery of deucravacitinib ranged from 95.34% to 103.80% and remained stable under different conditions. After successful validation, the method was used for pharmacokinetic profiling of deucravacitinib in rats following oral administration.

456

项与氘可来昔替尼相关的新闻（医药）

2025-07-29

·医药笔记

BMS成立自免NewCo：贝恩资本投资3亿美元，TLR7/8、TYK2、IL-2、IL-8、IL-10

▎Armstrong2025年7月28日，百时美施贵宝与贝恩资本宣布成立NewCo公司，从百时美施贵宝拆分5款自免新药，完成由贝恩资本领投的3亿美元融资。5款产品包括TLR7/8抑制剂Afimetoran、TYK2抑制剂BMS-986322、IL-2融合蛋白BMS-986326、IL-8靶向BMS-986481、IL-10靶向BMS-986498。百时美施贵宝在NewCo层面持股接近20%。百时美施贵宝在自免领域有2款已经上市的核心产品，分别为Orencia（阿巴西普）和Sotyktu（TYK2抑制剂）。总结百时美施贵宝自免在研管线还有泽纳仕引进的CD19抗体，LPAR1抑制剂Admiparant、CD19 CAR-T（NEX-T）、PKCθ抑制剂、BMS-986454等。此次拆分自免NewCo的核心产品为TLR7/8抑制剂Afimetoran，目前处于系统性红斑狼疮的二期临床阶段。今年5月，德国默克宣布TLR7/8抑制剂Enpatoran在系统性红斑狼疮二期临床中，超过90%的患者疾病活动度达到具有临床意义的降低，正在推进全球三期临床试验。国内方面，拓领博泰聚焦开发选择性的TLR8抑制剂、TLR7抑制剂，首发管线已经推进到临床阶段。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床2期抗体药物偶联物临床3期

2025-07-29

·BioPharmaDive

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Dive Brief:Bristol Myers Squibb and investment firm Bain Capital have joined forces to form a new biotechnology startup built around five of the pharmaceutical companys experimental immune disease drugs.According to Bristol Myers, the yet-to-be-named company will start with a $300 million funding commitment led by Bain Capital, three clinical-stage drug prospects and two Phase 1-ready medicines. The drugs target promising mechanisms in autoimmune diseases like lupus, plaque psoriasis and atopic dermatitis, the firms said Monday.Bristol Myers will get a 20% equity stake in the startup and could receive milestones tied to the success of the five drug programs and royalties on any eventual sales. Dan Lynch, a former Bristol Myers executive, will serve as its executive chairman and interim CEO.Dive Insight:One of the many ways to build a biotech startup involves plucking ready-made drugs from the shelves of pharmaceutical companies and surrounding them with an executive team devoted to their progress.That strategy eliminates the lengthy and costly drug discovery process, giving venture investors the chance at quicker returns. It also enables large drugmakers to cash in on pipeline projects that might have stalled or may no longer be a strategic fit.Since its formation eight years ago, Bain Capitals life sciences division has employed this plan multiple times. In 2017, it teamed up with Pfizer and other investors to launch Springworks Therapeutics along with four of the pharmaceutical companys experimental therapies. A year later, Bain Capital again joined with Pfizer to co-found Cerevel Therapeutics around a group of neuroscience drugs. Both have been acquired in multibillion-dollar deals since 2023.(Bain Capital has also built companies, like Aiolos Bio and Timberlyne Therapeutics, around medicines in-licensed from China.)Bain Capital is hoping for similar success with a handful of drugs that dont match Bristol Myers future plans. The three already in clinical testing are afimetoran, which blocks a pair of toll-like receptors and is being developed for lupus; a drug that, like Bristol Myers marketed medicine Sotyktu, inhibits TYK2; and an IL2 fusion protein being studied against lupus and atopic dermatitis. Two other biologics ready for testing target the signaling proteins IL8 and IL10, respectively.These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients, said Bristol Myers senior vice president of business development, Julie Rozenblyum, in a statement. Bain Capitals exceptional track record in building successful life science companies by providing focused development and dedicated resources makes them ideally suited to advance these assets to realize their full promise.While Bristol Myers intends to continue investing in immunology, the company has made a strategic shift to focus on drugs with the potential to “reset the immune system and promote tissue repair, it said in the statement. Those programs include a cell therapy for autoimmune diseases and a multifunctional antibody for so-called IgG4-related disease that its working on with Zenas Biopharma.Robert Plenge, Bristol Myers executive vice president and chief research officer, will serve on the spinoffs board along with Lynch. Bain Capitals Nicholas Downing, Adam Koppel and Andrew Kaplan are also directors. '

并购免疫疗法

2025-07-24

·药事纵横

全球首创口服IL-23靶向药！强生银屑病新药Icotrokinra申报上市

7月21日，全球医疗巨头强生公司与ProtagonistTherapeutics共同宣布，已向FDA提交全球首个IL-23受体靶向口服肽类药物Icotrokinra的新药申请，用于治疗12岁及以上中重度斑块状银屑病患者。如顺利获批，Icotrokinra将成为全球首个通过口服给药方式精确靶向IL-23受体的银屑病治疗药物，打破目前以注射用生物制剂为主的市场格局。关于斑块状银屑病斑块状银屑病不仅是一种皮肤疾病，更是一种系统性炎症性疾病。患者皮肤表面形成隆起的鳞屑斑块，在浅肤色人群中呈红色，在深肤色人群中则可能表现为紫色、灰色或深棕色。这种疾病在全球影响着超过1.25亿人，其中仅美国就有约800万患者,近四分之一患者病情达到中重度程度。2021年发表在《美国医学会皮肤病学杂志》的研究确认，银屑病困扰着约3%的美国成年人口，相当于约750万人，这些患者不仅承受着皮肤的瘙痒与疼痛，还经常面临心理健康问题和社交障碍。当前治疗方法主要有两类：生物制剂和小分子药物。然而，现有疗法在给药方式、疗效持久性和安全性方面均有局限，大量患者需求仍未得到满足。关于IcotrokinraIcotrokinra（研发代号JNJ-77242113或JNJ-2113）代表着一类全新的治疗模式。作为全球首创的口服肽类药物，它能够高精度选择性阻断IL-23受体，这正是斑块状银屑病炎症反应的核心通路。这种创新药物以皮摩尔级亲和力与IL-23受体结合，在人类T细胞中表现出对IL-23信号的强效选择性抑制作用，其分子设计使其能够精确靶向疾病核心机制，同时避免影响其他无关生物通路。与传统小分子药物相比，肽类药物具有更少的脱靶效应，可以更特异性地靶向细胞受体，与生物制剂相比，口服给药方式则大大提高了治疗便利性。胰岛素和GLP-1类药物是肽类药物成功应用的典范，Icotrokinra有望将这一成功扩展到免疫介导疾病领域。临床实证此次新药申请基于ICONIC临床开发项目中四项关键III期研究的坚实数据，包括ICONIC-LEAD、ICONIC-TOTAL、ICONIC-ADVANCE1和ICONIC-ADVANCE2研究。2025年3月在美国皮肤病学会年会上公布的ICONIC-LEAD研究结果显示，治疗第16周时，Icotrokinra组65%的患者达到IGA评分0或1（皮肤完全或几乎完全清除），而安慰剂组仅为8%。在衡量银屑病严重程度的另一关键指标PASI90方面，Icotrokinra组达到50%响应率，安慰剂组仅有4%。疗效随时间持续增强，到第24周时，74%患者达到IGA0/1，65%达到PASI90。在2025年世界儿童皮肤病学大会上公布的亚组分析显示，12岁以上青少年患者群体中也观察到类似疗效，皮肤完全或几乎完全清除率显著高于安慰剂组。ICONIC-TOTAL研究特别关注了难治部位的治疗效果。在涉及头皮银屑病的患者中，66%使用Icotrokinra的患者达到头皮特异性IGA评分0/1，而安慰剂组仅11%。在生殖器银屑病患者中有效率也显著提升。最引人注目的是ICONIC-ADVANCE1和2研究结果，这两项头对头试验证明Icotrokinra在主要疗效终点上显著优于已上市药物氘可来昔替尼（百时美施贵宝的Sotyktu）。安全性与治疗优势汇总安全性数据显示，Icotrokinra组（49.1%）与安慰剂组（51.9%）出现不良事件的患者比例相近，未发现新的安全性信号。强生创新医药免疫皮肤病与呼吸疾病领域负责人LizaO’Dowd博士指出：“鉴于我们研究的广度和深度，以及迄今为止报告的强劲临床结果，我们相信Icotrokinra有潜力改变医生和患者对斑块状银屑病护理的认知，为这种免疫介导疾病的治疗建立新的标准。”ICONIC-LEAD研究负责人RobertBissonnette博士补充道：“这些研究结果充满希望，表明Icotrokinra治疗有望为患者提供独特的组合优势——皮肤完全清除、良好的安全性以及每日一次口服给药的便利性。”强生公司已启动III期ICONIC-ASCEND研究，计划将Icotrokinra与该公司现有的生物制剂Stelara进行头对头比较。该公司还启动了Icotrokinra与Sotyktu的对比研究。市场前景预测根据ProtagonistTherapeutics与强生达成的合作协议，该合作总金额高达10亿美元。Protagonist已收到3.375亿美元预付款和里程碑付款，还有资格获得6.3亿美元潜在里程碑付款以及6-10%的销售分成。业内分析人士预测，Icotrokinra的销售峰值有望超过50亿美元，这主要基于其卓越的临床数据、口服给药便利性以及在多种IL-23介导疾病中的潜在应用价值。银屑病治疗市场目前由注射用生物制剂主导，包括强生自身的Stelara（乌司他单抗）、诺华的Cosentyx（司库奇尤单抗）和礼美的Taltz（依奇珠单抗）等。Icotrokinra的口服给药方式可能重塑这一价值数百亿美元的市场格局。市场研究分析师指出：“作为一种首创的口服疗法，Icotrokinra可能颠覆当前以注射用生物制剂为主导的治疗模式。口服给药的便利性与优异的临床数据结合，使其可能成为患者和医疗专业人员的首选。”应用拓展方面Icotrokinra的潜力不止于斑块状银屑病。IL-23通路在多种免疫介导疾病中起关键作用，包括银屑病关节炎、溃疡性结肠炎和克罗恩病等。强生公司表示，ICONIC临床开发项目的长期数据，包括ICONIC-LEAD和ICONIC-TOTAL研究中至少52周的治疗数据，以及评估疗效持久性的随机撤药分析结果，正在准备在未来的医学会议上发布。目前，强生已启动III期ICONIC-ASCEND试验，这是首个旨在证明口服药物（Icotrokinra）优于注射用生物制剂（乌司他单抗）的头对头研究。同时，公司正在评估该药物在其他IL-23介导疾病中的应用潜力，有望扩大其治疗范围。参考信息：[1]强生IL-23R口服环肽抑制剂向FDA递交上市申请-多肽圈[2]Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis[3]Protagonist Therapeutics Inc (PTGX) Submits NDA for Icotrokinra to FDA | PTGX stock news药事纵横投稿须知：稿费已上调，欢迎投稿

临床3期临床1期临床2期生物类似药

100 项与氘可来昔替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11817	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
红皮病性银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
寻常性银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
脓疱型银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
斑块状银屑病	美国	Bristol Myers Squibb Co.	2022-09-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	申请上市	美国	Bristol Myers Squibb Co.	2025-07-21
幼年特发性关节炎	临床3期	美国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	中国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	巴西	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	保加利亚	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	捷克	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	德国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	意大利	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	罗马尼亚	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	西班牙	Bristol Myers Squibb Co.	2025-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03881059 (Pubmed \| Rheumatol Ther)	临床2期	银屑病关节炎	203	Deucravacitinib 6 mg	選廠製範觸壓簾齋顧築(淵顧願憲憲淵廠壓積廠) = 襯襯選遞簾網襯願築鑰觸獵餘壓構簾簾構糧獵 (願築齋觸壓遞壓構衊範 )	积极	2025-07-05
				Deucravacitinib 12 mg	選廠製範觸壓簾齋顧築(淵顧願憲憲淵廠壓積廠) = 積鹽廠廠選齋壓蓋築觸觸獵餘壓構簾簾構糧獵 (願築齋觸壓遞壓構衊範 )
NCT04908189 (POETYK PsA-2, EULAR2025) 人工标引	临床3期	银屑病关节炎	729	Deucravacitinib 6mg once daily	獵蓋壓壓衊齋糧願範鬱(製窪簾鬱選範製膚遞衊) = 鹽網餘網願蓋廠獵顧簾遞襯簾鹽獵夢選範衊襯 (繭築鬱顧廠簾憲衊鹹淵 ) 更多	积极	2025-06-11
				Placebo	獵蓋壓壓衊齋糧願範鬱(製窪簾鬱選範製膚遞衊) = 遞遞觸鑰選鬱鏇憲選蓋遞襯簾鹽獵夢選範衊襯 (繭築鬱顧廠簾憲衊鹹淵 ) 更多
NCT06091956 (CTgov)	临床2期	毛发扁平苔癣 \| 前额纤维化脱发 \| 手掌和足底脓疱病	12	Deucravacitinib	網襯襯遞憲選窪鏇淵廠 = 構壓鏇鹹鏇範範醖鏇夢艱願襯餘網淵窪構遞鏇 (網廠憲獵範願膚衊憲襯, 鑰醖齋鹹遞構艱遞壓夢 ~ 顧構夢範憲築衊簾繭廠) 更多	-	2025-06-08
NCT05478499 (CTgov)	临床4期	头皮银屑病	154	Deucravacitinib	窪淵鹹鏇鹽繭衊獵選繭 = 齋蓋淵衊鹹範繭構壓觸糧艱製襯簾鬱繭齋艱鬱 (蓋繭選衊醖窪構衊廠鏇, 廠顧膚鹽鬱糧餘夢糧艱 ~ 鏇簾鏇積鹹衊簾淵蓋觸) 更多	-	2025-03-13
NCT04908189 (POETYK PsA-2 \| IM011-055, NEWS) 人工标引	临床3期	银屑病关节炎	730	氘可来昔替尼	齋壓醖鏇鏇獵壓糧鏇顧(窪壓膚鹹簾簾鹽齋鬱鹽) = 鬱襯積鹽繭繭鹹積齋積遞網鏇膚糧獵憲製範醖 (齋壓醖願積淵構築窪鹽 ) 达到更多	积极	2025-03-10
				安慰剂	齋壓醖鏇鏇獵壓糧鏇顧(窪壓膚鹹簾簾鹽齋鬱鹽) = 廠餘膚鹹窪齋積範窪鹹遞網鏇膚糧獵憲製範醖 (齋壓醖願積淵構築窪鹽 ) 达到更多
NCT03624127 \| NCT04036435 \| NCT03611751 (POETYK PSO-LTE, PipelineReview) 人工标引	临床3期	斑块状银屑病	-	deucravacitinib (1-year)	夢襯簾觸醖鏇淵選範積(遞廠齋餘願襯獵獵顧鏇) = 憲獵鑰膚簾顧築顧積願鏇膚襯衊築鹽鑰壓遞範 (遞蓋簾鹽齋構廠遞蓋餘 ) 更多	积极	2025-02-17
				deucravacitinib (5-year)	夢襯簾觸醖鏇淵選範積(遞廠齋餘願襯獵獵顧鏇) = 觸齋窪蓋糧簾餘膚蓋願鏇膚襯衊築鹽鑰壓遞範 (遞蓋簾鹽齋構廠遞蓋餘 ) 更多
NCT03252587 (PAISLEY, Pubmed \| Lupus Sci Med)	临床2期	系统性红斑狼疮	363	Deucravacitinib 3 mg twice daily	網繭憲製遞願製鏇範衊(願簾壓觸構醖襯獵鹹鹽) = 餘膚遞範繭遞範選餘壓鹹選鑰廠鬱築壓窪遞鏇 (製襯壓製繭鏇夢鬱壓鏇 ) 更多	积极	2025-01-01
				Deucravacitinib 6 mg twice daily	網繭憲製遞願製鏇範衊(願簾壓觸構醖襯獵鹹鹽) = 膚衊鹽糧獵觸製襯壓糧鹹選鑰廠鬱築壓窪遞鏇 (製襯壓製繭鏇夢鬱壓鏇 ) 更多
NCT04908189 (POETYK PsA-2, Company_Website) 人工标引	临床3期	银屑病关节炎	730	deucravacitinib	鏇餘醖艱顧鹹鏇選糧齋(選鏇顧衊鹽繭構製蓋範) = significantly greater proportion of Sotyktu -treated patients achieving ACR20 response. 鹹網網廠蓋齋鹹鏇獵遞 (鏇觸窪鹽築壓齋觸觸窪 ) 达到更多	积极	2024-12-23
				Placebo
NCT04908202 (POETYK PsA-1, Company_Website) 人工标引	临床3期	银屑病关节炎	670	deucravacitinib	餘範餘顧顧蓋蓋築網觸(鬱構餘網構艱廠夢襯鏇) = significantly greater proportion of Sotyktu -treated patients achieving ACR20 response. 餘淵積蓋艱製鑰齋鹹蓋 (膚窪餘遞鏇壓廠憲醖襯 ) 达到更多	积极	2024-12-23
				Placebo
NCT03624127 \| NCT04036435 \| NCT03611751 (POETYK PSO-1, PSO-2, and LTE trials, Pubmed \| JAMA Dermatol)	临床3期	斑块状银屑病	1,519	Deucravacitinib 6 mg once daily	齋遞壓齋願憲鹹遞鹽鹽(獵憲夢廠選繭淵餘鹹壓) = 蓋積廠醖齋憲繭遞遞糧鏇鹹鹽夢艱願構鹹選遞 (夢鑰襯窪窪鹽獵鹽顧積, 215.4 ~ 243.9) 更多	积极	2024-11-27
				Apremilast 30 mg twice daily	齋遞壓齋願憲鹹遞鹽鹽(獵憲夢廠選繭淵餘鹹壓) = 窪積積遞齋壓鏇壓淵繭鏇鹹鹽夢艱願構鹹選遞 (夢鑰襯窪窪鹽獵鹽顧積, 137.1 ~ 153.0) 更多